LIVN
LivaNova PLC NASDAQ Listed Oct 19, 2015$78.50
+0.00%
vs $78.50
Mkt Cap $4.3B
52w Low $41.02
93.9% of range
52w High $80.95
50d MA $69.94
200d MA $62.58
P/E (TTM)
-17.6x
EV/EBITDA
—
P/B
3.6x
Debt/Equity
0.4x
ROE
-20.2%
P/FCF
24.7x
RSI (14)
64.80
ATR (14)
$2.44
Beta
0.97
50d MA
$69.94
200d MA
$62.58
Avg Volume
797.5K
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
20 Eastbourne Terrace · London, X0 W2 6LG · GB
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | TNS | 0.85 | 0.41 | -51.8% | 66.26 | +1.7% | +7.0% | +1.3% | -2.5% | +2.4% | +1.0% | — |
| Feb 25, 2026 | TNS | 0.80 | 0.86 | +7.5% | 70.29 | +0.3% | +1.0% | -0.6% | -0.5% | -2.6% | -4.6% | — |
| Nov 5, 2025 | TNS | 0.92 | 1.11 | +20.8% | 50.81 | +0.7% | -2.4% | +1.8% | +0.9% | +3.5% | +7.5% | — |
| Aug 6, 2025 | TNS | 0.84 | 1.05 | +25.0% | 47.36 | +1.0% | +2.4% | +0.7% | +1.5% | +2.2% | +4.8% | — |
| May 7, 2025 | TNS | 0.75 | 0.88 | +17.3% | 43.50 | +1.7% | +1.3% | -0.0% | +2.7% | -2.6% | -1.2% | — |
| Feb 25, 2025 | TNS | 0.80 | 0.81 | +1.2% | 41.70 | -1.7% | -0.6% | -1.3% | +1.7% | +0.2% | -0.4% | — |
| Oct 30, 2024 | TNS | 0.71 | 0.90 | +26.8% | 51.34 | -0.5% | +0.5% | -0.9% | -4.1% | +1.4% | +4.9% | — |
| Jul 31, 2024 | TNS | 0.79 | 0.93 | +17.7% | 49.40 | +0.9% | -2.2% | -2.8% | -3.7% | +1.3% | -2.4% | — |
| May 1, 2024 | TNS | 0.45 | 0.73 | +62.2% | 62.62 | +0.0% | +0.5% | +2.0% | -2.4% | +0.8% | -1.1% | — |
| Feb 21, 2024 | TNS | 0.79 | 0.87 | +10.1% | 56.82 | -0.1% | -1.0% | +1.6% | -2.0% | -0.1% | -1.4% | — |
| Nov 1, 2023 | TNS | 0.62 | 0.73 | +17.7% | 50.04 | +1.9% | -2.7% | +2.7% | -2.7% | -2.2% | -0.7% | — |
| Jul 26, 2023 | TNS | 0.58 | 0.78 | +34.5% | 58.87 | +0.9% | -2.6% | +0.9% | +1.1% | +0.2% | -1.9% | — |
| May 3, 2023 | BMO | 0.41 | 0.43 | +4.9% | 47.50 | -0.5% | -0.2% | +0.2% | -0.8% | -0.8% | +0.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 27 | Barclays | Maintains | Equal Weight → Equal Weight | — | $71.00 | $70.52 | -0.7% | -0.6% | -0.5% | -2.6% | -4.6% | -0.9% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $69.05 | $64.16 | -7.1% | +1.8% | +1.0% | -0.6% | -0.5% | -2.6% |
| Jan 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $64.95 | $64.66 | -0.4% | -0.8% | -3.2% | -1.7% | -0.8% | +3.8% |
| Jan 7 | Stifel | Maintains | Buy → Buy | — | $64.12 | $64.32 | +0.3% | +0.8% | +0.5% | -0.8% | -3.2% | -1.7% |
| Dec 17 | Mizuho | Maintains | Outperform → Outperform | — | $63.08 | $62.74 | -0.5% | +0.0% | -1.6% | +1.2% | +0.4% | +0.3% |
| Nov 13 | Baird | Maintains | Outperform → Outperform | — | $56.62 | $56.62 | +0.0% | -2.5% | +0.3% | -3.1% | +0.5% | +0.0% |
| Nov 13 | Mizuho | Maintains | Outperform → Outperform | — | $56.62 | $56.62 | +0.0% | -2.5% | +0.3% | -3.1% | +0.5% | +0.0% |
| Nov 6 | Baird | Maintains | Outperform → Outperform | — | $50.81 | $51.17 | +0.7% | -2.4% | +1.8% | +0.9% | +3.5% | +7.5% |
| Sep 3 | Needham | Maintains | Buy → Buy | — | $56.92 | $56.81 | -0.2% | -0.6% | +2.8% | -0.3% | +0.6% | +0.7% |
| Aug 21 | Barclays | Maintains | Equal Weight → Equal Weight | — | $53.39 | $53.37 | -0.0% | -1.0% | +5.8% | +0.8% | +0.4% | -0.2% |
| May 20 | Wolfe Research | Upgrade | Peer Perform → Outperform | — | $43.97 | $44.87 | +2.0% | +2.1% | -2.7% | -1.1% | -3.0% | +5.1% |
| May 13 | Needham | Maintains | Buy → Buy | — | $45.23 | $45.04 | -0.4% | -2.6% | -1.2% | +0.6% | +1.3% | -1.0% |
| May 8 | Baird | Maintains | Outperform → Outperform | — | $43.50 | $44.23 | +1.7% | +1.3% | -0.0% | +2.7% | -2.6% | -1.2% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $43.50 | $44.23 | +1.7% | +1.3% | -0.0% | +2.7% | -2.6% | -1.2% |
| Mar 17 | Needham | Maintains | Buy → Buy | — | $39.24 | $39.50 | +0.7% | +5.5% | -2.4% | +1.1% | -1.0% | -2.3% |
| Mar 7 | Barclays | Maintains | Equal Weight → Equal Weight | — | $39.99 | $39.85 | -0.4% | -2.1% | -5.5% | +5.5% | +0.0% | -1.3% |
| Mar 3 | Goldman Sachs | Maintains | Buy → Buy | — | $41.63 | $42.23 | +1.4% | +0.2% | -0.4% | -1.7% | -2.2% | -2.1% |
| Feb 26 | Mizuho | Maintains | Outperform → Outperform | — | $41.70 | $41.01 | -1.7% | -0.6% | -1.3% | +1.7% | +0.2% | -0.4% |
| Feb 26 | Needham | Maintains | Buy → Buy | — | $41.70 | $41.01 | -1.7% | -0.6% | -1.3% | +1.7% | +0.2% | -0.4% |
| Feb 26 | Stifel | Maintains | Buy → Buy | — | $41.70 | $41.01 | -1.7% | -0.6% | -1.3% | +1.7% | +0.2% | -0.4% |
| Jan 28 | Needham | Maintains | Buy → Buy | — | $49.53 | $49.75 | +0.4% | +2.0% | +0.4% | -0.2% | -1.4% | -3.8% |
| Nov 25 | Needham | Maintains | Buy → Buy | — | $51.32 | $51.49 | +0.3% | +0.8% | -2.0% | +3.5% | +0.0% | -0.4% |
| Nov 12 | Needham | Maintains | Buy → Buy | — | $51.81 | $52.00 | +0.4% | +2.3% | +1.1% | -2.4% | -0.4% | +0.8% |
| Oct 31 | Needham | Maintains | Buy → Buy | — | $51.34 | $51.08 | -0.5% | +0.5% | -0.9% | -4.1% | +1.4% | +4.9% |
| Oct 31 | Baird | Maintains | Outperform → Outperform | — | $51.34 | $51.08 | -0.5% | +0.5% | -0.9% | -4.1% | +1.4% | +4.9% |
| Oct 31 | Mizuho | Maintains | Outperform → Outperform | — | $51.34 | $51.08 | -0.5% | +0.5% | -0.9% | -4.1% | +1.4% | +4.9% |
| Sep 17 | Baird | Upgrade | Neutral → Outperform | — | $48.79 | $50.37 | +3.2% | +4.5% | +0.1% | +0.3% | -0.9% | +1.1% |
| Aug 28 | Baird | Maintains | Neutral → Neutral | — | $46.60 | $46.50 | -0.2% | +3.7% | +3.9% | +0.3% | -1.6% | -1.0% |
| Aug 1 | Baird | Maintains | Neutral → Neutral | — | $49.40 | $49.86 | +0.9% | -2.2% | -2.8% | -3.7% | +1.3% | -2.4% |
| Jul 31 | Needham | Maintains | Buy → Buy | — | $51.30 | $53.27 | +3.8% | -3.7% | -2.2% | -2.8% | -3.7% | +1.3% |
| Jul 25 | Stifel | Maintains | Buy → Buy | — | $53.77 | $54.19 | +0.8% | -0.6% | +0.3% | -2.5% | -1.9% | -3.7% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $60.03 | $52.63 | -12.3% | -12.0% | +1.1% | -1.1% | -2.0% | +2.0% |
| May 2 | Baird | Maintains | Neutral → Neutral | — | $62.62 | $62.63 | +0.0% | +0.5% | +2.0% | -2.4% | +0.8% | -1.1% |
| May 2 | Mizuho | Maintains | Buy → Buy | — | $62.62 | $62.63 | +0.0% | +0.5% | +2.0% | -2.4% | +0.8% | -1.1% |
| May 1 | Needham | Maintains | Buy → Buy | — | $55.75 | $59.90 | +7.4% | +12.3% | +0.5% | +2.0% | -2.4% | +0.8% |
| Mar 27 | Mizuho | Maintains | Buy → Buy | — | $54.39 | $54.69 | +0.6% | +2.7% | +0.1% | -1.4% | -1.5% | -0.7% |
| Mar 20 | Needham | Maintains | Buy → Buy | — | $50.34 | $51.25 | +1.8% | +12.5% | -0.6% | -0.5% | -2.8% | -0.1% |
| Feb 27 | Barclays | Maintains | Equal Weight → Equal Weight | — | $55.97 | $56.31 | +0.6% | -0.1% | -1.4% | -0.5% | +0.8% | +1.1% |
| Feb 26 | Barclays | Maintains | Equal Weight → Equal Weight | — | $57.12 | $56.86 | -0.5% | -2.0% | -0.1% | -1.4% | -0.5% | +0.8% |
| Feb 22 | Baird | Maintains | Neutral → Neutral | — | $56.82 | $56.78 | -0.1% | -1.0% | +1.6% | -2.0% | -0.1% | -1.4% |
| Feb 22 | Mizuho | Maintains | Buy → Buy | — | $56.82 | $56.78 | -0.1% | -1.0% | +1.6% | -2.0% | -0.1% | -1.4% |
| Feb 21 | Needham | Maintains | Buy → Buy | — | $52.60 | $55.50 | +5.5% | +8.0% | -1.0% | +1.6% | -2.0% | -0.1% |
| Feb 20 | Mizuho | Upgrade | Neutral → Buy | — | $49.88 | $50.92 | +2.1% | +5.5% | +8.0% | -1.0% | +1.6% | -2.0% |
| Nov 17 | Needham | Maintains | Buy → Buy | — | $47.24 | $47.64 | +0.8% | -1.0% | +0.2% | -7.3% | +1.4% | +0.2% |
| Oct 23 | Needham | Maintains | Buy → Buy | — | $49.41 | $49.18 | -0.5% | -2.5% | +0.5% | -1.6% | -1.1% | +0.1% |
| Jul 27 | Barclays | Maintains | Equal Weight → Equal Weight | — | $58.87 | $59.41 | +0.9% | -2.6% | +0.9% | +1.1% | +0.2% | -1.9% |
| Jul 27 | Baird | Maintains | Outperform → Outperform | — | $58.87 | $59.41 | +0.9% | -2.6% | +0.9% | +1.1% | +0.2% | -1.9% |
| Jul 26 | Needham | Maintains | Buy → Buy | — | $53.58 | $58.05 | +8.4% | +9.9% | -2.6% | +0.9% | +1.1% | +0.2% |
| May 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $47.48 | $47.58 | +0.2% | -0.8% | -0.8% | +0.5% | +0.1% | +0.1% |
| May 3 | Needham | Maintains | Buy → Buy | — | $47.13 | $45.24 | -4.0% | +0.8% | -0.2% | +0.2% | -0.8% | -0.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | Bianchi FrancescoDir | — | Sell | 1,200 | $80.19 | $96K | 9,584 | +0.00% | — |
| May 26, 2026 | Bianchi FrancescoDir | — | Sell | 1,800 | $75.75 | $136K | 7,228 | -1.16% | -2.73% |
8-K
LivaNova PLC -- 8-K Filing
LivaNova PLC's shareholders approved advisory votes on executive compensation and ratified PwC as auditor, signaling investor confidence in management's pay practices and governance oversight.
Jun 11
8-K · 2.02
!! High
LivaNova PLC -- 8-K 2.02: Earnings Results
LivaNova PLC reported Q1 2026 financial results, signaling operational performance that investors should monitor for growth trends and margin improvements in its neuromodulation and cardiac surgery device segments.
May 6
8-K
LivaNova PLC -- 8-K Filing
LivaNova's VNS Therapy gained CMS reimbursement coverage for drug-resistant epilepsy while its cloud-based digital platform received FDA approval, potentially expanding market access and revenue streams.
Feb 25
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Primecap Management Co/ca/ | 4,207,052 | $267M | — | Mar 2026 |
| 2 | Fmr Llc | 2,666,674 | $169M | Added | Mar 2026 |
| 3 | Millennium Management | 2,438,671 | $155M | Reduced | Mar 2026 |
| 4 | Aqr Capital Management Llc | 2,494,372 | $154M | Added | Mar 2026 |
| 5 | Artisan Partners Limited Partnership | 2,122,816 | $135M | Reduced | Mar 2026 |
| 6 | Invesco Ltd. | 1,624,209 | $103M | Added | Mar 2026 |
| 7 | Vanguard Portfolio Management Llc | 1,344,289 | $85M | New | Mar 2026 |
| 8 | Congress Asset Management Co | 1,274,820 | $81M | New | Mar 2026 |
| 9 | Greenlight Capital | 1,229,316 | $64M | Added | Dec 2023 |
| 10 | Nuveen, Llc | 920,343 | $58M | — | Mar 2026 |
| 11 | Victory Capital Management Inc | 833,268 | $53M | Reduced | Mar 2026 |
| 12 | Northern Trust Corp | 666,310 | $42M | Added | Mar 2026 |
| 13 | Vanguard Capital Management Llc | 648,233 | $41M | New | Mar 2026 |
| 14 | Hood River Capital Management Llc | 636,540 | $40M | New | Mar 2026 |
| 15 | Soleus Capital Management, L.p. | 582,500 | $37M | Added | Mar 2026 |
| 16 | Morgan Stanley | 582,918 | $36M | Added | Dec 2025 |
| 17 | Bank Of America Corp /de/ | 533,017 | $34M | Reduced | Mar 2026 |
| 18 | Janus Henderson Group Plc | 471,379 | $30M | New | Mar 2026 |
| 19 | Jpmorgan Chase & Co | 464,142 | $28M | Added | Mar 2026 |
| 20 | Walleye Capital Llc | 427,190 | $27M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$4.31B
Enterprise Value
$4.04B
P/E (TTM)
-17.64x
Forward P/E
18.64x
PEG Ratio
0.03x
P/B
3.57x
P/S
3.08x
P/FCF
24.70x
EV/EBITDA
—
Shares Out
54.5M
Financials (TTM)
Revenue
$1.39B
Net Income
-$242.5M
EBITDA
-$129.5M
Free Cash Flow
$173.2M
Op Cash Flow
$254.3M
EPS Basic
$-4.45
EPS Diluted
$-4.45
EPS Forward
$4.21
Gross Margin
67.7%
Op Margin
14.4%
Net Margin
-17.5%
Balance Sheet
Total Assets
$2.61B
Total Liab.
$1.41B
Total Equity
$1.20B
Cash
$635.6M
LT Debt
$393.5M
Book Value/Sh
$22.02
Debt/Equity
0.39x
Current Ratio
1.36
Quick Ratio
1.16
Returns & Growth
ROE
-20.2%
ROA
-9.3%
ROIC
10.9%
Rev Growth YoY
+10.7%
EPS Growth YoY
-480.3%
Price Returns
2W
+3.0%
1M
+22.8%
3M
+4.5%
6M
+15.7%
12M
+70.6%
Technicals
52W High
$80.95
52W Low
$41.02
50d MA
$69.94
200d MA
$62.58
RSI (14)
64.80
ATR (14)
$2.44
Beta
0.97
Avg Volume
797K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$75.88
High
$85.00
Low
$66.00
Median
$77.50
Data updated apr 25, 2026 7:19pm
· Source: financialmodelingprep.com